Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) reached a new 52-week high on Monday . The stock traded as high as $11.16 and last traded at $11.13, with a volume of 136,243 shares traded. The stock had previously closed at $10.71.

Separately, ValuEngine raised shares of Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th.

The company’s market cap is $147.05 million. The firm has a 50 day moving average of $8.43 and a 200-day moving average of $7.66.

In other news, Director Xiaopeng Li purchased 89,636 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The stock was bought at an average cost of $8.50 per share, with a total value of $761,906.00. Following the purchase, the director now directly owns 206,350 shares of the company’s stock, valued at $1,753,975. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 27.50% of the stock is owned by company insiders.

A hedge fund recently bought a new stake in Oramed Pharmaceuticals stock. Virtu KCG Holdings LLC bought a new stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 16,077 shares of the biotechnology company’s stock, valued at approximately $125,000. Virtu KCG Holdings LLC owned about 0.12% of Oramed Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 1.34% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Receive News & Stock Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.